BCL6 (B-cell CLL/lymphoma 6)

P1, N=18, Recruiting, Lapo Alinari | Trial completion date: Mar 2027 --> Mar 2028 | Trial primary completion date: Mar 2027 --> Mar 2028

Ultimately, the patient was diagnosed with fluid overload-associated large B-cell lymphoma and treated with rituximab, cyclophosphamide, vincristine sulfate, and prednisone, but passed away three months after diagnosis. It may be mistaken for other conditions such as primary effusion lymphoma or other diffuse large B-cell lymphomas. The presence of a Human Herpesvirus-8-negative effusion-based lymphoma in an elderly immunocompetent patient without nodal or tissue involvement should prompt consideration of fluid overload-associated large B-cell lymphoma.

Our study provides a comprehensive assessment of the spectrum of MYC, BCL2, and BCL6 rearrangements based on FISH and IHC analysis results.

P1/2, N=27, Recruiting, Medical University of South Carolina | Trial completion date: Dec 2026 --> Sep 2027

Transcriptomic profiling further revealed upregulation of CXCR4 and BCL6 following Forskolin treatment, and functional blockade of these pathways attenuated the beneficial effects of Forskolin, underscoring their critical roles in reinforcing CAR-T cell stemness. Our findings highlight a novel strategy that integrates stem cell-reprogramming agents to enhance CAR-T cell stemness and provide potential therapeutic targets to improve the efficacy of CAR-T cell therapy against solid tumors.

We suggest that HGESS with BCOR alterations may warrant reclassification as 'BCOR-altered uterine sarcomas'.

Of the patients treated for their positive BCL6 results, 20 (86%) were treated with leuprolide acetate, 9 (39%) with an aromatase inhibitor, and 1 (4%) was surgically managed with a laparoscopy in preparation for their frozen embryo transfer...The relationship between BCL6 and endometriosis may not be the golden solution to a single marker focus for testing, or for subsequent therapy planning among infertility patients. Clinicians should be cautious in using single marker testing for diagnosing and treating endometriosis in patients without strong additional therapeutic evidence.

P1/2, N=46, Active, not recruiting, Tanabe Pharma Corporation | Trial primary completion date: Dec 2025 --> Aug 2028

P1, N=12, Completed, Institute of Hematology & Blood Diseases Hospital, China | Unknown status --> Completed

This study highlights the aggressive nature of AITL and identifies several readily accessible laboratory parameters as important prognostic factors. The protective effect of PD-1 positivity on survival outcomes warrants further investigation. While CHOP/CHOPE remains the standard treatment, the addition of novel targeted therapies shows promise for improving patient outcomes in this challenging lymphoma subtype.

Oral administration of BMS-986458 results in dose-dependent pharmacokinetics, pharmacodynamics, and significant antitumor efficacy in mouse models of lymphoma. A potential first-in-class agent, BMS-986458, is currently being evaluated in a phase 1/2 clinical trial (NCT06090539) for patients with relapsed/refractory NHL.

P1/2, N=58, Completed, National Research Center for Hematology, Russia | Recruiting --> Completed | Trial completion date: Mar 2026 --> Nov 2025